JP2019501882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501882A5 JP2019501882A5 JP2018528340A JP2018528340A JP2019501882A5 JP 2019501882 A5 JP2019501882 A5 JP 2019501882A5 JP 2018528340 A JP2018528340 A JP 2018528340A JP 2018528340 A JP2018528340 A JP 2018528340A JP 2019501882 A5 JP2019501882 A5 JP 2019501882A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- derived
- beclin
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 50
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 15
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 15
- 241000713666 Lentivirus Species 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 239000013603 viral vector Substances 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 102000004072 Beclin-1 Human genes 0.000 claims 5
- 108090000524 Beclin-1 Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- 241000125945 Protoparvovirus Species 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 241001430294 unidentified retrovirus Species 0.000 claims 4
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 102000010310 Beclin-2 Human genes 0.000 claims 2
- 108050001838 Beclin-2 Proteins 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101710150451 Protein Bel-1 Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021162777A JP2022002530A (ja) | 2015-12-03 | 2021-10-01 | ウイルスベクター効率を改善するための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306924 | 2015-12-03 | ||
| EP15306924.0 | 2015-12-03 | ||
| EP16194180 | 2016-10-17 | ||
| EP16194180.2 | 2016-10-17 | ||
| PCT/EP2016/079304 WO2017093330A1 (en) | 2015-12-03 | 2016-11-30 | Compositions and methods for improving viral vector efficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162777A Division JP2022002530A (ja) | 2015-12-03 | 2021-10-01 | ウイルスベクター効率を改善するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501882A JP2019501882A (ja) | 2019-01-24 |
| JP2019501882A5 true JP2019501882A5 (enExample) | 2019-10-24 |
| JP7350485B2 JP7350485B2 (ja) | 2023-09-26 |
Family
ID=57485463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528340A Active JP7350485B2 (ja) | 2015-12-03 | 2016-11-30 | ウイルスベクター効率を改善するための組成物及び方法 |
| JP2021162777A Pending JP2022002530A (ja) | 2015-12-03 | 2021-10-01 | ウイルスベクター効率を改善するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021162777A Pending JP2022002530A (ja) | 2015-12-03 | 2021-10-01 | ウイルスベクター効率を改善するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11371061B2 (enExample) |
| EP (1) | EP3383896A1 (enExample) |
| JP (2) | JP7350485B2 (enExample) |
| CN (1) | CN108699135B (enExample) |
| CA (1) | CA3004971A1 (enExample) |
| WO (1) | WO2017093330A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10596264B2 (en) * | 2011-06-30 | 2020-03-24 | Genethon | Peptides with viral infection enhancing properties and their use |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| EP3831281B1 (en) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Devices and systems for biomedical targeting and delivery |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| JP2020530463A (ja) * | 2017-08-10 | 2020-10-22 | アーディジェン， エルエルシー | ウイルスの細胞内送達のためのペプチドおよびナノ粒子 |
| CN107686523B (zh) * | 2017-09-15 | 2021-05-14 | 山西大学 | 一种肿瘤酸度响应自噬诱导多肽及其制备方法和应用 |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP7394493B2 (ja) * | 2019-07-31 | 2023-12-13 | レモネックス インコーポレイテッド | 抗癌剤および多孔性シリカ粒子の製造方法 |
| WO2022046800A2 (en) * | 2020-08-24 | 2022-03-03 | University Of Southern California | Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases |
| WO2022173893A1 (en) * | 2021-02-15 | 2022-08-18 | Biomarin Pharmaceutical Inc. | USE OF HISTIDINE RICH PEPTIDES AS A TRANSFECTION REAGENT FOR rAAV AND rBV PRODUCTION |
| CN113713082B (zh) * | 2021-08-27 | 2023-07-18 | 福建医科大学 | 一种用于阿尔茨海默症的纳米自噬诱导剂及其制备方法与应用 |
| CN114316065B (zh) * | 2021-10-29 | 2023-09-22 | 新乡医学院 | 小分子肽及其应用、细胞培养基、核酸分子 |
| WO2024243639A1 (en) * | 2023-05-31 | 2024-12-05 | The Florey Institute Of Neuroscience And Mental Health | Autophagy-inducing peptides |
| WO2025179154A1 (en) * | 2024-02-21 | 2025-08-28 | Vycellix, Inc. | Compositions and methods for enhancing transduction efficiency of viral vectors with heparin and analogues thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083979B1 (en) | 1994-03-25 | 2006-08-01 | Indiana University Foundation | Methods for enhanced retroviral-mediated gene transfer |
| US20130202646A1 (en) * | 2010-02-25 | 2013-08-08 | San Diego State University (Sdsu) Foundation | Compositions and methods for modulating autophagy |
| US10596264B2 (en) * | 2011-06-30 | 2020-03-24 | Genethon | Peptides with viral infection enhancing properties and their use |
| EP2812347B1 (en) * | 2012-02-11 | 2016-08-24 | Board Of Regents, The University Of Texas System | Autophagy-inducing peptide |
| WO2014109728A1 (en) | 2013-01-11 | 2014-07-17 | The Scripps Research Institute | Methods and compositions for enchancing transduction efficiency of retroviral vectors |
| US20140271584A1 (en) | 2013-03-15 | 2014-09-18 | The Research Foundation For The State University Of New York | Methods and Compositions for Direct Reprogramming of Somatic Cells to Stem Cells, and Uses of these Cells |
| CA2924969A1 (en) * | 2013-09-18 | 2015-03-26 | Ndsu Research Foundation | Compositions and methods for treating conditions associated with y-herpesviruses |
| WO2016119856A1 (en) | 2015-01-29 | 2016-08-04 | Universite De Strasbourg | Autophagy-inducing molecules for increasing insulin release |
| EP3141680B1 (en) * | 2015-09-09 | 2018-01-31 | U-Shin Italia S.p.A. | Electronic handle for a vehicle door |
| WO2017055370A1 (en) * | 2015-09-28 | 2017-04-06 | Fondazione Telethon | Treatment of bone growth disorders |
| US10993983B2 (en) * | 2016-03-18 | 2021-05-04 | Trustees Of Tufts College | Cyclic peptide epitopes and small-molecule mimics for inducing autophagy |
| EP3481411A4 (en) * | 2016-07-11 | 2020-07-22 | University of North Texas Health Science Center at Fort Worth | TREATING GLAUCOMA AND OTHER EYE DISEASES |
| WO2018222723A1 (en) * | 2017-05-30 | 2018-12-06 | Vertex Pharmaceuticals Incorporated | C3 fusion protein and methods of making and using thereof |
-
2016
- 2016-11-30 EP EP16806032.5A patent/EP3383896A1/en not_active Withdrawn
- 2016-11-30 US US15/772,902 patent/US11371061B2/en not_active Expired - Fee Related
- 2016-11-30 WO PCT/EP2016/079304 patent/WO2017093330A1/en not_active Ceased
- 2016-11-30 JP JP2018528340A patent/JP7350485B2/ja active Active
- 2016-11-30 CA CA3004971A patent/CA3004971A1/en active Pending
- 2016-11-30 CN CN201680070996.0A patent/CN108699135B/zh not_active Expired - Fee Related
-
2021
- 2021-10-01 JP JP2021162777A patent/JP2022002530A/ja active Pending
-
2022
- 2022-05-23 US US17/750,705 patent/US20230117384A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7507529B2 (en) | Oligonucleotides originating from sequences coding for the surface component of PTLV envelope proteins and their uses | |
| JP7350485B2 (ja) | ウイルスベクター効率を改善するための組成物及び方法 | |
| Simmonds et al. | Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1 | |
| Tsurutani et al. | Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells | |
| Aktar et al. | Structural basis of genomic RNA (gRNA) dimerization and packaging determinants of mouse mammary tumor virus (MMTV) | |
| Wang et al. | Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging | |
| Ansari et al. | Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity | |
| Dube et al. | The complete genomic sequence of a BLV strain from a Holstein cow from Argentina | |
| Möbius et al. | A functionally selective synthetic mimic of the HIV‐1 co‐receptor CXCR4 | |
| Langley et al. | Nucleotide sequence analysis of puma lentivirus (PLV-14): genomic organization and relationship to other lentiviruses | |
| Weiss et al. | Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA | |
| CN112442514B (zh) | 慢病毒包装载体系统、慢病毒及其构建方法、试剂盒 | |
| Zhuang et al. | Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways | |
| Maury | Regulation of equine infectious anemia virus expression | |
| Kono et al. | Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5αs against human immunodeficiency virus type 2 infection | |
| Vahlenkamp et al. | A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism | |
| Kurosu et al. | Human immunodeficiency virus type 1 subtype C exhibits higher transactivation activity of Tat than subtypes B and E | |
| Krishnan et al. | Identification of a putative Gag binding site critical for feline immunodeficiency virus genomic RNA packaging | |
| Vahlenkamp et al. | Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus | |
| Dash et al. | Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection | |
| Guo et al. | The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA | |
| Soezi et al. | Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery | |
| Avidan et al. | Expression and characterization of the integrase of bovine immunodeficiency virus | |
| US7381817B2 (en) | LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus | |
| US20110263460A1 (en) | Compositions and methods for producing replication competent human immunodeficiency virus (hiv) |